AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
AbbVie's Phase 3 INTREPID trial of lutikizumab in moderate-to-severe hidradenitis suppurativa met its primary endpoint, with 31.4% HiSCR75 response at Week 16 versus 23.4% on placebo (p≤0.001), plus all 8 ranked secondary endpoints. Lutikizumab also significantly reduced HS-related skin pain by Week 8 and cut flare occurrence (18.4% vs 28.1%), with a safety profile similar to placebo and no new safety signals in the 1,400-patient study.
Key figures
- Drug Name
- lutikizumab (ABT-981)
- Phase Of Trial
- Phase 3
- Nrs3 week8
- 26.2% vs 15.0% placebo
- Nrs30 week8
- 36.0% vs 22.8% placebo
- Hiscr75 week16
- 31.4% vs 23.4% placebo (p≤0.001)
- Hs flare rate 16wk
- 18.4% vs 28.1% placebo
- Patients randomized
- 1400
- Secondary endpoints met
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.